Compare TELA & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TELA | ATNM |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 36.8M |
| IPO Year | 2019 | 2013 |
| Metric | TELA | ATNM |
|---|---|---|
| Price | $0.74 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $3.31 | ★ $4.00 |
| AVG Volume (30 Days) | 56.4K | ★ 104.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.80 | 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,300,000.00 | $81,000.00 |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $15.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.56 | N/A |
| 52 Week Low | $0.67 | $1.02 |
| 52 Week High | $2.48 | $1.95 |
| Indicator | TELA | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 43.37 |
| Support Level | $0.67 | $1.02 |
| Resistance Level | $1.20 | $1.25 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 34.38 | 38.74 |
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.